AAV GCase Gene Therapy for Sustained Gaucher Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Gaucher disease, such as enzyme replacement therapy and substrate reduction therapy, require frequent administration and are associated with side effects, necessitating a more effective and less frequent therapeutic approach.
Innovation Solution
Development of adeno-associated virus (AAV) vectors engineered to express beta-glucocerebrosidase (GCase) protein, optimized for reduced CpG di-nucleotides and incorporating specific transcription control regions, secretion signal peptides, and hepatotropic capsids, to enhance GCase expression and reduce immunogenicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If enzyme replacement therapy (ERT) is used to treat Gaucher disease, then GCase activity is compensated and symptoms are reduced, but frequent intravenous infusions are required and patients develop neutralizing antibodies that reduce efficacy
Solution Approach 1:
The AAV vector delivers the GCase gene in advance to patient cells, establishing endogenous production capacity before disease symptoms worsen. This preliminary genetic modification enables sustained enzyme production without repeated administrations, resolving the contradiction between maintaining therapeutic efficacy and reducing administration frequency
Solution Approach 2:
The AAV-mediated gene therapy enables patient cells to produce their own GCase enzyme autonomously. The transduced cells continuously express functional GCase protein, eliminating the need for external enzyme supplementation and avoiding antibody formation against exogenous enzyme, thus achieving both sustained efficacy and reduced treatment burden
2Object-affected harmful factors
If substrate reduction therapy (SRT) is used to inhibit GlcCer biosynthesis, then glucocerebroside accumulation is reduced, but the therapy requires lifelong administration and is associated with multiple side effects
Solution Approach 1:
Instead of using small molecule inhibitors that cause side effects, the invention converts the harmful accumulation problem into a beneficial outcome by directly addressing the root cause - GCase deficiency. The AAV vector delivers functional GCase gene, enabling cells to properly metabolize GlcCer without requiring continuous pharmacological inhibition, thus eliminating side effects while achieving the same therapeutic goal
Solution Approach 2:
The invention changes the therapeutic parameter from pharmacological substrate inhibition to genetic enzyme supplementation. By modifying the fundamental approach from small molecule therapy to gene therapy, the treatment achieves sustained reduction of glucocerebroside accumulation without the recurring side effects associated with lifelong SRT administration
Data Source
AI summary
The disclosure describes improved vectors, such as adeno-associated virus (AAV) vectors, for expressing beta-gluco-cerebrosidase (GCase) in transduced cells, and use of such vectors to increase the amount of GCase in subjects experiencing a GCase deficiency, such as subjects with Gaucher disease Type 1.